A peptide fragment of amylin
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Amylin (1-13) (human, mouse, rat), (trifluoroacetate salt)

Item No. 24893

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanine, cyclic (2→7)-disulfide, trifluoroacetate salt
Synonyms
  • IAPP (1-13) (human, mouse rat)
  • Islet Amyloid Polypeptide (1-13) (human. mouse, rat)
Molecular Formula
C54H95N19O19S2 • XCF3COOH
Formula Weight
1378.6
Purity
≥95%
Formulation (Request formulation change)
A lyophilized powder
Solubility(Learn about Variance in Solubility)
Water: 1 mg/ml
SMILES
[H]N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@]([C@@H](C)O)([H])C1=O)=O)C)=O)=O)=O)CSSC[C@H](N1)C(N[C@H](C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@H](C(O)=O)C)=O)=O)=O)=O)=O)C)=O)=O.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C54H95N19O19S2.C2HF3O2/c1-22(2)18-32(46(84)64-25(5)53(91)92)67-44(82)30(13-11-17-61-54(59)60)65-45(83)31(14-15-36(57)77)66-51(89)39(27(7)75)71-41(79)23(3)62-48(86)34-20-93-94-21-35(69-43(81)29(56)12-9-10-16-55)49(87)68-33(19-37(58)78)47(85)73-38(26(6)74)50(88)63-24(4)42(80)72-40(28(8)76)52(90)70-34;3-2(4,5)1(6)7/h22-35,38-40,74-76H,9-21,55-56H2,1-8H3,(H2,57,77)(H2,58,78)(H,62,86)(H,63,88)(H,64,84)(H,65,83)(H,66,89)(H,67,82)(H,68,87)(H,69,81)(H,70,90)(H,71,79)(H,72,80)(H,73,85)(H,91,92)(H4,59,60,61);(H,6,7)/t23-,24-,25-,26+,27+,28+,29-,30-,31-,32-,33-,34-,35-,38-,39-,40-;/m0./s1
InChi Key
QDNNQESKUPEKNZ-CWEXIWGYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $130

    Add

    1 mg

    $247

    Add
    Product Description

    Amylin (1-13) is a peptide fragment of amylin (Item Nos. 24274 | 24275), which is a peptide hormone secreted from pancreatic β-cells that reduces food intake, decreases glucagon secretion, slows gastric emptying, and increases satiety.1,2,3,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lutz, T.A. Control of food intake and energy expenditure by amylin - therapeutic implications. Int. J. Obes. 33(Suppl. 1), S24-S27 (2009).

    2. Mack, C.M., Soares, C.J., Wilson, J.K., et al. Davalintide (AC2307), a novel amylin-mimetic peptide: Enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int. J. Obes. (Lond) 34(2), 385-395 (2010).

    3. Gómez-Foix, A.M., Rodriguez-Gil, J.E., and Guinovart, J.J. Anti-insulin effects of amylin and calcitonin-gene-related peptide on hepatic glycogen metabolism. Biochem. J. 276(Pt 3), 607-610 (1991).

    4. Vine, W., Beaumont, K., Gedulin, B., et al. Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene-related peptide and amylin in rats. Eur. J. Pharmacol. 314(1-2), 115-121 (1996).